Advertisement
U.S. markets closed

OptiNose, Inc. (OPTN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.6500+0.0900 (+5.77%)
At close: 04:00PM EST
1.6500 0.00 (0.00%)
After hours: 05:11PM EST

OptiNose, Inc.

1020 Stony Hill Road
Suite 300
Yardley, PA 19067
United States
267 364 3500
https://www.optinose.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees141

Key Executives

NameTitlePayExercisedYear Born
Dr. Ramy A. Mahmoud M.D., M.P.H.CEO & Director731.59kN/A1965
Mr. Michael F. Marino Esq.Chief Legal Officer & Corporate Secretary604.24kN/A1976
Mr. Anthony J. KrickVice President & Chief Accounting OfficerN/AN/A1981
Mr. Jonathan NeelyVice President of Investor Relations & Business OperationsN/AN/AN/A
Ms. Karen E. BrophyChief Human Resources Officer & VP of Human ResourcesN/AN/A1963
Mr. Paul SpenceChief Commercial OfficerN/AN/A1968
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. OptiNose, Inc. has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Orexia Therapeutics to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Corporate Governance

OptiNose, Inc.’s ISS Governance QualityScore as of February 1, 2024 is 7. The pillar scores are Audit: 8; Board: 6; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.